Ozanimod hydrochloride is a Small Molecule owned by Bristol-Myers Squibb, and is involved in 47 clinical trials, of which 25 were completed, 17 are ongoing, and 5 are planned.
Ozanimod works by modulating S1P 1 and 5 receptor. S1P 1 and 5 receptor selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. It works by selectively sequestering circulating lymphocytes, blunting and cause a reduction in circulating lymphocytes by disrupting the normal migration of lymphocytes from the lymphoid organs into the blood. In the presence of S1P 1 and 5 receptor modulator, lymphocytes lose their ability to sense S1P concentration gradients. As a consequence, selective S1P receptor agonists block lymphocyte migration, thereby reducing peripheral lymphocyte counts and preventing lymphocyte recruitment to sites of inflammation.
The revenue for Ozanimod hydrochloride is expected to reach a total of $14.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Ozanimod hydrochloride NPV Report.
Ozanimod hydrochloride was originated by Scripps Research Institute and is currently owned by Bristol-Myers Squibb.
Ozanimod hydrochloride Overview
Ozanimod hydrochloride (Zeposia) is an immunomodulatory agent. It is formulated as hard gelatin capsules for oral route of administration. Zeposis indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and also indicated for the treatment moderate to severe ulcerative colitis Zeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic agent.
Ozanimod (RPC-1063) is under development for the treatment of Coronavirus disease 2019 (COVID-19), moderate to severe ulcerative colitis and Crohn’s disease in pediatrics and adults. It is a new chemical entity. The drug candidate is administered orally as a capsule. It is the second generation S1P1 receptor modulator. The drug candidate is based on GPCR structure-based drug design platform.
Bristol-Myers Squibb Overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.
Quick View – Ozanimod hydrochloride
|Highest Development Stage|